Catalent Pharma Solutions has made two senior appointments to support its recently established joint ventures in China for its Softgel Technologies and Clinical Supply Solutions (CSS) businesses.
Dr Weiyan ‘Jackson’ Zhu has joined as Catalent's Country General Manager for China, while Yufeng (Paul) Cao becomes Site Operations Director for the 31,000ft2 Catalent (Shanghai) Clinical Trial Supplies Co facility, which is currently under construction. Zhu and Cao will both be based in Shanghai.
Zhu will focus on business development and government agency interaction. He will also liaise with Catalent’s local teams, which are currently being put in place, to assist with the start-up of the company’s new operations.Zhu joins Catalent following a long tenure at Boehringer Ingelheim, where he was the company’s first, mainland China appointment in its 120-year history. After joining Boehringer Ingelheim as a Sales Manager in 1998, Zhu held roles of increasing responsibility, including Regional Business Manager of Europe. Most recently, he was Vice President and Head of Boehringer Ingelheim’s consumer healthcare division in China.
Yufeng (Paul) Cao
Cao will have overall day-to-day responsibility for Catalent and ShangPharma’s China Joint Venture business and will be in charge of establishing the new Shanghai clinical trial operation. He will lead Catalent’s local China CSS team to complete the site construction and launch operations by late summer. Cao will be in charge of developing the supply chain for the CSS operation and developing a customer service team.
Prior to joining Catalent, Cao was most recently General Manager for Fisher Clinical Service (Beijing, China). Before this he worked for Zuellig Pharma and has extensive experience in drug distribution.
